Given the critical role of ERK and YAP per se in tumor development,43,44 we believe our results encourage further investigation of whether a combination of FDA-approved MEK inhibitors (trametinib, cobimetinib, binimetinib) and agents that inhibit YAP activation is effective in treating OSCC.45 Here, MAP2K7 is linked to neoplasm.